Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer

PURPOSE: TP53 missense mutations may help to identify prostate cancer (PCa) with lethal potential. Here, we pre-analytically, analytically and clinically validated a robust immunohistochemistry (IHC) assay to detect subclonal and focal TP53 missense mutations in PCa. <p>EXPERIMENTAL DESIGN: The p53 IHC assay was performed in a CLIA-accredited laboratory on the Ventana Benchmark immunostaining system. p53 protein nuclear accumulation was defined as any p53 nuclear labeling in >10% of tumor cells. 54 formalin fixed paraffin embedded (FFPE) cell lines from the NCI-60 panel and 103 FFPE PCa tissues (88 primary adenocarcinomas, 15 metastases) with known TP53 mutation status were studied. DU145 and VCaP xenografts were subjected to varying fixation conditions to investigate the effects of pre-analytic variables. Clinical validation was performed in two partially overlapping radical prostatectomy (RP) cohorts.</p> <p>RESULTS: p53 nuclear accumulation by IHC was 100% sensitive for detection of TP53 missense mutations in the NCI-60 panel (25/25 missense mutations correctly identified). Lack of p53 nuclear accumulation was 86% (25/29) specific for absence of TP53 missense mutation. In FFPE prostate tumors, the positive predictive value (PPV) of p53 nuclear accumulation for underlying missense mutation was 84% (38/45), while the negative predictive value (NPV) was 97% (56/58). In a cohort of men who experienced biochemical recurrence after RP, the multivariable hazard ratio for metastasis among cases with p53 nuclear accumulation compared to those without was 2.55 (95% CI: 1.1-5.91).</p> <p>CONCLUSIONS: IHC is widely available method to assess for the presence of deleterious and heterogeneous TP53 missense mutations in clinical PCa specimens.

from Cancer via ola Kala on Inoreader http://ift.tt/2oyiCMN
via IFTTT